@michellelsun@lennysan Electric screwdriver https://t.co/rCZuOnTQh9 with https://t.co/jB1hYx1p4g Massive time saver. Nobody should be regularly using manual screwdrivers. Number of companies without this is astonishing. Get a load of cheap metric hex bits from aliexpress. H1.5,2,2.5,3,3.5,4
@eladgil funding cuts and misallocation of capital (e.g. bioprinting, blindly funding highest credentialed people, uneducated investors), low risk tolerance. not surprising at all. Biotech hasn't been a priority for US/investors for a long time. blood bath for most of bio workforce.
@design_proteins https://t.co/c5BIVNiq94. Have you seen this? Incidentally, i have all the equipment needed for that, heavily discounted off retail. I may know 1 or 2 people who could help program this, would have to reach out to them to see for sure.
Biolab robots have been a big topic on here this week. Not everyone $2m+ to spend, but plenty of labs have an OpenTrons and we're happy to now share a standard Golden Gate Cloning Workflow for their latest models, that we call "SLOWPOKE"
https://t.co/8DJxkCYmdP
Just got an opentrons flex in. Fairly new. Has 1-50uL 8 channel and 5-1000uL 96 channel pipette, plus a hepa/uv module. Pricing is ~70% of retail. Can buy all or individual items
https://t.co/Yf4g1JtoLf $SANA data show survival of islets for 1yr no immunosuppression. In CAR-T trial, their anti-rejection tech worked in 11 humans. Critics cite in vitro data showing problem NK cell subsets, but doesn't appear in vivo so far. In vivo data seem more conclusive
@Jn66039675@2035Bio was it this? page 9? https://t.co/6k9FS9qssK I haven't been able to find anything else. Looked at the ADR paper they referenced on page 8, but didn't see mention of CD47. that ADR paper was from 2020. paper highlighting importance of CD47 level was 2021, 1st one in my list
@Jn66039675@2035Bio do you have a source for this? I can't find it. Note that CD47 level is critical. 5 sources 2019-25 mice,monkey,human showing CD47 works: 1) 10.1084/jem.20200839, 2) 10.1038/s41587-023-01784-x, 3) 10.1056/NEJMoa2503822, 4) 10.1016/j.isci.2024.111492, 5) 10.1038/s41587-019-0016-3
@Dadbod4evah@2035Bio not at this price, i mean the investors were only willing to pay $1.15. I see possible failure modes for $IPSC. e.g. macrophage mediated rejection. the synthetic TASR itself could elicit immune response. they have enough money to answer these questions though
@RowgInvestor@2035Bio I think the magnitude of the moves preceding the private offering on no news, and now knowing Cohen's point72 was involved, is in hindsight very suspect. Possible insider trading for sure. Cohen's previous firm already convicted of insider trading though, so doubt SEC will help